History

1992

  • Medical Strategy GmbH founded by Dr. Michael Fischer

1998

  • Authorization to manage financial portfolios granted by the German Federal Banking Supervisory Authority (Bundesaufsichtsamt für Kreditwesen/BAKred, now BaFin)
  • Acceptance of first fund mandate

2000

  • Initiation and launch of MEDICAL BioHealth, start of partnership with Oppenheim Asset Management in Luxembourg
  • Medical Strategy strengthened by the appointment of Harald Schwarz and Jürgen Harter

2001

  • Named “Fund of the Year” for the first time by FINANZEN magazine

2004

  • Standard & Poor’s give MEDICAL BioHealth its first AA rating
  • Dr. Michael Fischer awarded three gold medals by Sauren Fonds Research for the first time

2005

  • Initiation and launch apo Medical Opportunities, fund management for approx. 50% of the fund volume. Start of partnership with apo asset, a subsidiary of the Deutsche Apotheker- und Ärztebank.

2006

  • Lipper Fund Award received for MEDICAL BioHealth

2009

  • Dr. Michael Fischer receives Sauren Gold Award

2010

  • Standard & Poor’s awards the MEDICAL BioHealth its long-term quality seal, the ‘5-year long-term grading’, for the first time
  • 10th anniversary of MEDICAL BioHealth

2011

  • MEDICAL BioHealth awarded its first Gold Fund Grading and “5 year long-term grading” by S&P Capital IQ

2014

  • Launch of apo Medical Opportunities Institutionell, fund management for approx. 50% of the fund volume

2011

  • Investment advice (form 01/09/17 Fundmanagment) of RIM GLOBAL BIOSCIENCE

2017

  • Mario Linimeier is appointed Managing Director

2018

  • Medical Strategy was awarded with the Finance Research AWARD. In the segment of Independent Asset Managers in Germany, the company was rated as “Outstanding“.
  • At the “Funds Europe Awards” in London, Medical Strategy received a special commendation in the category “European Specialist Investment Firm of the Year.

2019

  • apoBank subsidiary takes a 25.1% stake in Medical Strategy.